FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

								(,											
1. Name and Address of Reporting Person* Gano Kyle						2. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC NBIX								eck all applic	,		on(s) to Iss 10% Ov Other (s	vner	
(Last) 12780 E	st) (First) (Middle) 780 EL CAMINO REAL					3. Date of Earliest Transaction (Month/Day/Year) 01/02/2024								below)		Deve	below)	·	
					_ 4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) SAN DII	EGO C.	A	92130)	_								X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip)					R	Rule 10b5-1(c) Transaction Indication													
Check this box to indicate that a transaction was made pursuant satisfy the affirmative defense conditions of Rule 10b5-1(c). See												on or written	plan th	nat is intende	d to				
		Tab	le I -	Non-Deri	ivativ	e Sec	curit	ties A	cquir	ed, D	isposed o	of, or E	eneficial	y Owned					
1. Title of Security (Instr. 3)			2. Transact Date (Month/Day		ear) Execu		eemed ution Date, th/Day/Year)		action (Instr.	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and				es ially Following	Form (D) o	r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3	ction(s)			(Instr. 4)		
Common Stock 01/02/202			024	24			M		68,884	A	\$19.59	19	9,134	D					
Common Stock 01/02/20			024	.4			S ⁽¹⁾		68,884	D	\$ 131.4716	6 ⁽²⁾ 130,250		0 D					
Common Stock 01/02/202			024	.4			M		6,116	Α	\$19.59	19.59 136			D				
Common Stock 01/02/202			024	24		S ⁽¹⁾		6,116	D	\$131.4429	13	30,250		D					
		•	Table								sposed of , converti			Owned					
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security			Execution Date, if any		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exer	cisable	Expiration Date	Title	Amount or Number of Shares						
Non- Qualified Stock Option	\$19.59	01/02/2024			M			68,884		(4)	01/16/2024	Commo		\$19.59	0		D		
Incentive Stock	\$19.59	01/02/2024			M			6,116		(4)	01/16/2024	Commo	n 6,116	\$19.59	0		D		

Explanation of Responses:

- 1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- 2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$130.76 to \$133.33. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- 3. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$130.76 to \$133.27. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- 4. The option was granted January 16, 2014 and vested in 48 equal monthly installments beginning February 16, 2014. These options will expire ten years from the date of grant on January 16, 2024.

Remarks:

Option

/s/ Darin Lippoldt, Attorney-In-01/04/2024 **Fact**

** Signature of Reporting Person

Stock

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.